stockrowAscendis Pharma A/S
ASND Healthcare Biotechnology
Ascendis Pharma A/S’s revenue for fiscal 2025 (year ended December 2025) was $814.8 million, up 107.1% from fiscal 2024.
- Revenue
- +119.9%
- EPS
- +612.3%
- Free cash flow
- +2,335.9%
- Total debt
- −41.8%
Quarter to June 2026, against a year earlier
Follow ASND
Alert me
Ascendis Pharma A/S (ASND) Shares outstanding
Ascendis Pharma A/S's shares outstanding at the end of fiscal 2025 was $60.6M, unchanged from fiscal 2024. At the end of the quarter to 30 June 2026 it was $68.3M. Over the past ten years it has ranged from $23.8M (fiscal 2015) to $60.6M (fiscal 2025) — the current reading is the highest in ten years. Ascendis Pharma A/S ranks 221st of 600 Biotechnology companies by shares outstanding.
Shares outstanding, annual
Embed this chart
Annual newest first
| Period | Shares outstanding | Change |
|---|---|---|
| FY2025 | $60.6M | 4.69% |
| FY2024 | $57.9M | 2.85% |
| FY2023 | $56.3M | 0.38% |
| FY2022 | $56.1M | 2.37% |
| FY2021 | $54.8M | 8.21% |
| FY2020 | $50.6M | 8.84% |
| FY2019 | $46.5M | 13.20% |
| FY2018 | $41.1M | 22.18% |
| FY2017 | $33.6M | 26.59% |
| FY2016 | $26.6M | 11.77% |
Quarterly newest first
| Period | Shares outstanding | Change |
|---|---|---|
| Jun 2026 | $68.3M | 5.89% |
| Mar 2026 | $64.5M | 6.46% |
| Dec 2025 | $60.6M | (0.25%) |
| Sep 2025 | $60.8M | (4.94%) |
| 42 more quarters | Free account |
Against its own ten years
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| SMMT Summit Therapeutics PLC compare | $778.2M |
| EXEL Exelixis, Inc. compare | $255.8M |
| BNTX BioNTech SE Sponsored ADR compare | $252.7M |
| INSM Insmed, Inc. compare | $218.8M |
| BBIO BridgeBio Pharma, Inc. compare | $196.0M |
| ALNY Alnylam Pharmaceuticals, Inc. compare | $138.0M |
| HALO Halozyme Therapeutics, Inc. compare | $122.6M |
| ASND Ascendis Pharma A/S | $68.3M |
| JAZZ Jazz Pharmaceuticals PLC compare | $64.7M |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item
More on ASND
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement